Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00778973 · ClinicalTrials.gov registry record · NA

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions

A NA study of Healthy, sponsored by Ranbaxy Laboratories Limited.

Completed
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT00778973: Completed NA study of Healthy, sponsored by Ranbaxy Laboratories Limited.

NCT00778973 is a NA study of Healthy that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 36 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00778973, a NA study of Healthy, has completed, sponsored by Ranbaxy Laboratories Limited.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study was to evaluate the relative bioavailability of the test formulation of sertraline 100 mg tablets with an already marketed reference formulation Zoloft® 100 mg tablets (Pfizer), under non-fasting conditions in healthy male and female adult subjects.

Conditions Studied

Interventions

  • DRUG sertraline 100 mg tablets

Study Locations (1)

Pennsylvania

  • Novum Pharmaceutical Research Services - Pittsburgh

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2005-08
Est. Completion 2005-10
Phase NA

Sponsor

Ranbaxy Laboratories Limited

44 total trials

What the Registry Record Tells You About NCT00778973

The ClinicalTrials.gov registry entry for NCT00778973 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which sertraline 100 mg tablets is the first listed.

NCT00778973 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00778973 about?

NCT00778973 is a clinical study titled "Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions". The purpose of this study was to evaluate the relative bioavailability of the test formulation of sertraline 100 mg tablets with an already marketed reference formulation Zoloft® 100 mg tablets (Pfizer), under non-fasting conditions in healthy male and female adult subjects.

What is the current status of trial NCT00778973?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2005-08. Estimated completion is 2005-10.

What conditions does trial NCT00778973 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00778973?

The interventions under investigation include: sertraline 100 mg tablets (DRUG).

Who is sponsoring clinical trial NCT00778973?

This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00778973 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.